Physician profile
Steven M Pray
NPI 1447333265
$4,305.66
in general payments reported to CMS, 2019-2025
37 companies · $832 in 2025
The $832 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $461 · 2021: $548 · 2022: $551 · 2023: $727 · 2024: $847 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,406.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $700.94 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $552.35 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.57 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $302.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $207.46 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $198.03 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $190.96 | 2019-2025 | Veozah |
| Lilly USA, LLC | $183.48 | 2020-2025 | Zepbound, Jardiance, Emgality |
| Mylan Specialty L.P. | $177.83 | 2019-2024 | Yupelri |
| Exact Sciences Corporation | $177.72 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $124.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.86 | 2019-2023 | Eliquis |
| Amgen INC. | $83.74 | 2020-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $82.98 | 2022-2024 | |
| Axsome Therapeutics, INC. | $69.23 | 2023-2025 | Auvelity, Sunosi |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $69.13 | 2019-2021 | |
| Inspire Medical Systems, INC. | $66.78 | 2025 | Inspire |
| Amarin Pharma, INC. | $52.34 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.79 | 2022-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $33.25 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $32.18 | 2021 | |
| Globus Medical, INC. | $30.00 | 2025 | Senza |
| Indivior INC. | $28.87 | 2024 | Sublocade |
| Corcept Therapeutics | $26.46 | 2025 | Korlym |
| Sanofi Pasteur INC. | $23.74 | 2023 | |
| Eisai INC. | $23.20 | 2021 | |
| Optos, INC. | $22.53 | 2021 | |
| Sumitomo Pharma America, INC. | $22.24 | 2024 | Gemtesa |
| Jazz Pharmaceuticals INC. | $22.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.89 | 2019 | |
| Orexo US, INC. | $21.06 | 2025 | Zubsolv |
| Allergan, INC. | $18.31 | 2020 | |
| Electromed, INC. | $15.44 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.81 | 2024 | Gvoke Hypopen |
| Kala Pharmaceuticals, INC. | $12.76 | 2021 | |
| Corium, LLC | $11.95 | 2024 | Azstarys |
| Esperion Therapeutics, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Pray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.